Causaly provides Covid-19 dataset to Bill and Melinda Gates' funded Global Health Drug Discovery Institute

Noelle Baquiche
Noelle Baquiche
published on March 05, 2020

At Causaly, we're honored to be supporting the 2019-nCoV Collective Research Initiative led by the Global Health Drug Discovery Institute in Beijing (GHDDI).

Launched on the 27th January in partnership with the School of Pharmaceutical Sciences (SPS) and Tsinghua University, the initiative is designed to make internal drug discovery platforms and resources available to external researchers to aid drug discovery efforts against the novel coronavirus (2019-nCoV) outbreak.

Causaly has machine-read, analyzed and mapped all existing knowledge on the corona virus genus, and supplied it to the initiative's information sharing platform, to support data collection efforts.

The main contents of the GHDDI 2019-nCoV platform include:


  1. Data mining and integration of historical drug discovery efforts against coronavirus (e.g. SARS/MERS) using AI and big data;

  2. Relevant preclinical and clinical data resources;

  3. Molecular chemical modeling and simulation data using computational tools;

  4. Latest scientific research progress on 2019-nCoV.


As part of our ongoing efforts to support Open Science and accelerate research into COVID-19, we are offering complimentary accounts for Causaly's open research dataset for all non-commercial research.

Get in touch to request access, or for more information.

Preclinical safety analysis using Artificial Intelligence on the example of Alzheimer’s Disease.
Application

Preclinical safety analysis using Artificial Intelligence on the example of Alzheimer’s Disease.

Causaly AI enables researchers to identify safety-relevant information in medical literature regarding a drug candidate. Preclinical experts can include this data in the preclinical study design to minimize the risks of unforeseen toxicities and increase chances of approval.

AI-supported Target identification for Systemic Lupus Erythematosus.
Application

AI-supported Target identification for Systemic Lupus Erythematosus.

In the field of SLE, with over 2,000 scientific papers published in 2020 alone, target identification experts need to stay on top of recent advancements. Causaly facilitates this process and enables potential target identification, investigation of underlying mechanism of action and druggability.

How Causaly AI is transforming translational research: Interview with Imad Yassin
Application

How Causaly AI is transforming translational research: Interview with Imad Yassin

An interview with Imad Yassin on how AI is transforming translational research and why Causaly is one of the biggest game-changers in the field he's seen to date.

Sign up for Causaly newsletter